glp 1 pharmacology GLP-1 GLP-1 and the kidney: from
Description
The introduction of these therapies represents a paradigm shift in obesity treatment
Plaintiffs allege that pharmaceutical companies failed to provide adequate warnings about these risks on product labels and in marketing materials
writingreview and editing, F.R.P., M.B., S.M
As a GLP-1 receptor agonist, Saxenda works differently from traditional appetite suppressants
Methodology We conducted a search for English-language original studies and meta-analyses published between 2010 and 2024 using PubMed, Medscape, and MEDLINE
